Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), an ophthalmic pharmaceutical company based in California, and the Choroideremia Research Foundation (CRF), a non-for-profit patient organisation focused on the… Read More »Kiora Pharmaceuticals Inc. have announced a partnership with the Choroideremia Research Foundation for novel treatments.
According to the ASRS Research and Safety in Therapeutics (ReST) Committee, a small number of cases of occlusive retinal vasculitis has been observed between 7… Read More »The American Society of Retina Specialists (ASRS) has reported at least six cases of occlusive retinal vasculitis following injection of Syfovre (pegcetacoplan).
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics… Read More »FDA has declined approval of Regeneron’s higher dose (8mg) of Eylea, understood to be a review of inspection findings at a third-party filler.
Nanoscope Therapeutics Inc., a company based in Bedford, Texas, has reported key data from a Phase 2b multi-centre RCT (NCT04945772) of “MCO-010” (sonpiretigene isteparvovec), an… Read More »Nanoscope Therapeutics Inc., have announced key results for Phase 2b (“RESTORE”) for the treatment of retinitis pigmentosa (RP) using optogenetic therapy.
Astellas Pharma Inc. (TSE: 4503) and IVERIC Bio, Inc. (NASDAQ: ISEE) have announced a definitive agreement on May 1st under which Astellas has agreed to… Read More »Astellas Pharma Inc., (TSE: 4503) is to acquire Iveric Bio Inc., (NASDAQ: ISEE) for a purchase of US$5.9bn.
A US company, LumiThera Inc., based in Seattle, WA has reported summary trial data on photo-biomodulation, termed “LIGHTSITE III” study, conducted by a multi-centre clinical… Read More »US “LIGHTSITE III” clinical trial data on photo-biomodulation (PBT) treatment of dry AMD has reported vision improvement for 24 months.
Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has announced new data on preparing AAV-based gene therapy programs to… Read More »Opus Genetics Inc., has announced new data on the potential of gene therapy treatments from RDH12- and MERTK-associated retinal degenerations.
Ocugen Inc., (NASDAQ:OCGN), an ophthalmic biopharmaceutical company based in Malvern, Pennsylvania, has announced preliminary safety and efficacy data of a Phase 1/2 study of “OCU400”,… Read More »Ocugen Inc., (NASDAQ: OCGN) has announced preliminary safety and efficacy data of a Phase 1/2 study for a modifier gene therapy candidate treating retinitis pigmentosa (RP)
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), a clinical stage company based in Lexington, Massachusetts, has reported the completion of the enrollment of a Phase 2 clinical… Read More »Aldeyra Therapeutics Inc., (NASDAQ: ALDX) reports the completion of enrollment in a Phase 2 study for methotrexate to treat Pro23His retinitis pigmentosa (RP)
Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has announced the acquisition of rights to two preclinical-stage AAV-based gene… Read More »Opus Genetics Inc., has announced the acquisition of rights to two preclinical-stage for inherited retinal diseases (IRDs) from Iveric Bio (NASDAQ: ISEE)
